以ERK1为媒介的中介细胞干细胞免疫调节可改善炎症性疾病
Qing Zhang1,2,3, Xiao Lei1,3, Fang Wang4
1State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration & National Clinical Research Center for Oral Diseases & Shaanxi International Joint Research Center for Oral Diseases, Center for Tissue Engineering, School of Stomatology, the Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
介酶干细胞 (MSC) 通过调节T细胞来治疗自身免疫性疾病. 在MSC中的ERK1对于这种调节至关重要,而Licochalcone A提高了MSC治疗的有效性.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 介质干细胞 (MSC) 通过调节免疫反应,特别是T细胞活性来研究治疗自身免疫性疾病 (AD).
- 细胞外调节激酶 (ERKs) 与MSC介导的T细胞亡有关,但其精确的机制尚未完全理解.
研究的目的:
- 阐明ERK1和ERK2在MSC中关于T细胞调节和亡的特定作用.
- 调查Licochalcone A (LA) 在增强基于MSC的ADS治疗中的潜力.
主要方法:
- 对ERK1缺乏和ERK2缺乏骨髓MSCs (BMMSCs) 的比较分析,以检测它们诱导T细胞亡的能力.
- 在BMMSC中对ETS2/AURKA/NF-κB/Fas/MCP-1信号级联激活的调查.
- 通过BMMSCs对调控性T细胞 (Treg) 上调和T助手17 (Th17) 细胞抑制的评估.
- 在性结肠炎和原诱导性关节炎的小鼠模型中,对MSC治疗疗效的利科哈尔康尼A (LA) 影响的评估.
主要成果:
- ERK1,但不是ERK2,缺少BMMSCs取消了T细胞亡诱导.
- 缺乏ERK1的BMMSC无法激活ETS2/AURKA/NF-κB/Fas/MCP-1级联,导致T细胞调节受损.
- 缺乏ERK1的BMMSC显示Tregs上调和抑制Th17细胞的能力降低.
- 在临床前的ADS模型中,利科哈尔康A治疗增强了MSC的治疗效果.
结论:
- ERK1在MSC介导的T细胞调节中发挥着关键作用,与ERK2.2不同.
- ETS2/AURKA/NF-κB/Fas/MCP-1通路对于ERK1介导的T细胞亡至关重要.
- 用利可卡尔康A治疗的MSC代表了提高基于MSC治疗自身免疫疾病的疗效的有希望的策略.
更多相关视频
07:45Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
Published on: September 1, 2017
09:10Mesenchymal Stem Cell Regulation of Macrophage Phagocytosis; Quantitation and Imaging
Published on: July 16, 2021
相关概念视频
Mesenchymal Stem Cells
Regulation of Hematopoietic Stem Cells
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
